BACE2 and Alzheimer disease: Given recent evidence for the physiological role of BACE2 as an AD-suppressor gene (Alić et al., 2021; Luo et al., 2022), further investigation is required to address whether cross-inhibition of BACE2 activity by non-selective or partially selective BACE1 inhibitors may diminish the benefit of BACE1 inhibition or contribute to the untoward worsening effect on ALF (if any) in preclinical AD.